Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 26;10(9):2093.
doi: 10.3390/biomedicines10092093.

Effects of Achieving Sustained Virologic Response after Direct-Acting Antiviral Agents on Long-Term Liver Fibrosis in Diabetics vs. in Non-Diabetic Patients with Chronic Hepatitis C Infection

Marian-Sorin Popescu  1 , Dan-Mihai Firu  1 , Vlad Pădureanu  1 , Cristina Maria Mărginean  1 , Radu Mitruț  2 , Andreea Letitia Arsene  3 , Dragoș Nicolae Mărgăritescu  4 , Daniela Calina  5 , Anca Oana Docea  6 , Paul Mitruț  1
Affiliations

Effects of Achieving Sustained Virologic Response after Direct-Acting Antiviral Agents on Long-Term Liver Fibrosis in Diabetics vs. in Non-Diabetic Patients with Chronic Hepatitis C Infection

Marian-Sorin Popescu et al. Biomedicines. .

Abstract

Because of the prevalence of HCV worldwide as well as its undiagnosed population due to a lack of screening, HCV can be considered a modern pandemic disease. In 2016, the World Health Organization (WHO) set goals for HCV's elimination that included a 65 percent reduction in mortality and an 80 percent reduction in newly infected cases by 2030. This study is a follow-up evaluation of 80 patients who received interferon-free treatment with direct-acting agents (DAA) for chronic HCV infection between the second half of 2017 and the end of 2018. They were assessed using a FibroMax test prior to DAA administration. Two pills/day of Ombitasvir 12.5 mg/Paritaprevir 75 mg/Ritonavir 50 mg and two pills/day of Dasabuvir 250 mg were given to the patients for 8 weeks. After treatment, all 80 patients in this study achieved an SVR (sustained virologic response), and the FibroMax test was performed three years later. Our study found that successfully treating HCV infection can play a significant role in reducing fibrosis in T2DM patients. In comparison to those of ActiTest and SteatoTest, FibroMax scores showed a significantly greater reduction in T2DM patients than in treatment-naive patients.

Keywords: FibroMax; direct-acting agents; hepatitis C viral infection; insulin resistance; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Distribution of changes in the FibroMax test scores after DAA treatment in non-T2DM patients versus in T2DM patients.
Figure 2
Figure 2
Changes in the FibroTest class after treatment in the T2DM and non-TDM2 groups.
Figure 3
Figure 3
Changes in the ActiTest class after treatment in the T2DM and non-TDM2 groups.
Figure 4
Figure 4
Changes in the SteatoTest class after treatment in the T2DM and non-TDM2 groups.
Figure 5
Figure 5
Changes in the NashTest class after treatment in the T2DM and non-TDM2 groups.
Figure 6
Figure 6
Changes in the AshTest class after treatment in the T2DM and non-TDM2 groups.
See this image and copyright information in PMC

References

    1. World Health Organization . Global Health Sector Strategy on Viral Hepatitis 2016–2021. World Health Organization; Geneva, Switzerland: 2016.
    1. Cooke G.S., Andrieux-Meyer I., Applegate T.L., Atun R., Burry J.R., Cheinquer H., Dusheiko G., Feld J.J., Gore C., Griswold M.G., et al. Accelerating the elimination of viral hepatitis: A Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol. Hepatol. 2019;4:135–184. doi: 10.1016/S2468-1253(18)30270-X. - DOI - PubMed
    1. Da Silva Filipe A., Sreenu V., Hughes J., Aranday-Cortes E., Irving W.L., Foster G.R., Agarwal K., Rosenberg W., Macdonald D., Richardson P., et al. Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries. J. Hepatol. 2017;67:1348–1350. doi: 10.1016/j.jhep.2017.06.035. - DOI - PubMed
    1. Chu J.Y.K., Ou J.J. Autophagy in HCV Replication and Protein Trafficking. Int. J. Mol. Sci. 2021;22:1089. doi: 10.3390/ijms22031089. - DOI - PMC - PubMed
    1. Rinaldi L., Nevola R., Franci G., Perrella A., Corvino G., Marrone A., Berretta M., Morone M.V., Galdiero M., Giordano M., et al. Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics. Cancers. 2020;12:1351. doi: 10.3390/cancers12061351. - DOI - PMC - PubMed

LinkOut - more resources